Phase 2 Cardiomyopathy Trial, Recruiting NCT06174220 Sponsor: Hamilton Health Sciences Corporation Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT06174220
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been found to carry a specific genetic change (variant) in one of these genes: PKP2, DSG2, DSC2, DSP, or JUP (note: JUP carriers must have the variant on both copies of the gene), OR you carry a specific variant called TMEM43-p.S358L (confirm with trial site)
  • A heart monitor worn for 7 days showed that, on average, you have at least 500 extra/irregular heartbeats (called PVCs) per day
  • You have either been diagnosed with a heart condition called ACM (arrhythmogenic cardiomyopathy), or you have been known to be a genetic carrier of a related variant, for at least 6 months before joining the trial

Who may not be able to join:

  • You have very severe heart failure (the most advanced stage, known as Class IV)
  • You have heart scarring caused by blocked heart arteries (coronary artery disease)
  • You have started, stopped, or changed the dose of certain heart rhythm medications (Class I or III anti-arrhythmics) within the last 3 months
  • You have a serious long-term liver disease
  • A blood test at screening shows your liver enzyme levels (ALT) are more than twice the normal upper limit
  • A blood test at screening shows your bilirubin levels (a liver marker) are above the normal upper limit, unless you have a known condition called Gilbert's syndrome — in which case, levels more than twice the upper limit would still exclude you (confirm with trial site)
  • You have a history of alcohol or drug use disorders
  • You regularly take certain strong medications that affect how the body processes drugs (called strong CYP3A4 inhibitors), such as clarithromycin, ketoconazole, itraconazole, ritonavir, or similar medicines (confirm full list with trial site)
  • A blood test shows your kidney function is below a certain level (confirm with trial site)
  • You are pregnant at the time of joining the trial
  • You are a woman who could become pregnant and are not using a highly effective form of contraception
  • You are a man who is sexually active with a woman who could become pregnant and are not using an acceptable form of contraception, unless you have had a surgical procedure making you sterile
  • You are unwilling to give your consent to participate or are unable to attend follow-up appointments
  • You have a known allergy or sensitivity to the study drug (tideglusib) or any of its ingredients, including an allergy to strawberry
  • You are currently taking certain other medications that are processed by the same pathway in the body (CYP3A4) and have a very narrow safe dosing range, such as warfarin or digoxin

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jason D Roberts, MD MAS, McMaster University and Population Health Research Institute

Phone: 905-521-2100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hamilton Health Sciences Corporation
Registry
ClinicalTrials.gov
Start date
21 March 2025
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

PVC burden

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov